236 related articles for article (PubMed ID: 32285369)
1. Dynamic Culture Systems and 3D Interfaces Models for Cancer Drugs Testing.
Fernandes DC; Canadas RF; Reis RL; Oliveira JM
Adv Exp Med Biol; 2020; 1230():137-159. PubMed ID: 32285369
[TBL] [Abstract][Full Text] [Related]
2. Bioreactors and Microfluidics for Osteochondral Interface Maturation.
Canadas RF; Marques AP; Reis RL; Oliveira JM
Adv Exp Med Biol; 2018; 1059():395-420. PubMed ID: 29736584
[TBL] [Abstract][Full Text] [Related]
3. Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.
Amirghasemi F; Adjei-Sowah E; Pockaj BA; Nikkhah M
Ann Biomed Eng; 2021 Aug; 49(8):1943-1972. PubMed ID: 33403451
[TBL] [Abstract][Full Text] [Related]
4. Microbioreactors for high-throughput cytotoxicity assays.
Yang ST; Zhang X; Wen Y
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):111-27. PubMed ID: 18175274
[TBL] [Abstract][Full Text] [Related]
5. 3D Engineering of Ocular Tissues for Disease Modeling and Drug Testing.
Boutin ME; Hampton C; Quinn R; Ferrer M; Song MJ
Adv Exp Med Biol; 2019; 1186():171-193. PubMed ID: 31654390
[TBL] [Abstract][Full Text] [Related]
6. 3D modeling in cancer studies.
Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
[TBL] [Abstract][Full Text] [Related]
7. Cancer drug discovery: recent innovative approaches to tumor modeling.
Lovitt CJ; Shelper TB; Avery VM
Expert Opin Drug Discov; 2016 Sep; 11(9):885-94. PubMed ID: 27454169
[TBL] [Abstract][Full Text] [Related]
8. Organotypic cancer tissue models for drug screening: 3D constructs, bioprinting and microfluidic chips.
Radhakrishnan J; Varadaraj S; Dash SK; Sharma A; Verma RS
Drug Discov Today; 2020 May; 25(5):879-890. PubMed ID: 32165322
[TBL] [Abstract][Full Text] [Related]
9. Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs.
van den Brand D; Massuger LF; Brock R; Verdurmen WP
Bioconjug Chem; 2017 Mar; 28(3):846-856. PubMed ID: 28122451
[TBL] [Abstract][Full Text] [Related]
10. Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery.
Agarwal P; Wang H; Sun M; Xu J; Zhao S; Liu Z; Gooch KJ; Zhao Y; Lu X; He X
ACS Nano; 2017 Jul; 11(7):6691-6702. PubMed ID: 28614653
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional in vitro tumor models for cancer research and drug evaluation.
Xu X; Farach-Carson MC; Jia X
Biotechnol Adv; 2014 Nov; 32(7):1256-1268. PubMed ID: 25116894
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment.
Yoshii Y; Furukawa T; Waki A; Okuyama H; Inoue M; Itoh M; Zhang MR; Wakizaka H; Sogawa C; Kiyono Y; Yoshii H; Fujibayashi Y; Saga T
Biomaterials; 2015 May; 51():278-289. PubMed ID: 25771018
[TBL] [Abstract][Full Text] [Related]
13. Monitoring tumor response to anticancer drugs using stable three-dimensional culture in a recyclable microfluidic platform.
Liu W; Xu J; Li T; Zhao L; Ma C; Shen S; Wang J
Anal Chem; 2015 Oct; 87(19):9752-60. PubMed ID: 26337449
[TBL] [Abstract][Full Text] [Related]
14. A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.
Heylman C; Sobrino A; Shirure VS; Hughes CC; George SC
Exp Biol Med (Maywood); 2014 Sep; 239(9):1240-54. PubMed ID: 24740872
[TBL] [Abstract][Full Text] [Related]
15. Regulation of mesenchymal stem cell 3D microenvironment: From macro to microfluidic bioreactors.
Sart S; Agathos SN; Li Y; Ma T
Biotechnol J; 2016 Jan; 11(1):43-57. PubMed ID: 26696441
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiologically relevant in vitro tumor models for drug screening.
Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
[TBL] [Abstract][Full Text] [Related]
17. 3D-3 Tumor Models in Drug Discovery for Analysis of Immune Cell Infiltration.
Osswald A; Hedrich V; Sommergruber W
Methods Mol Biol; 2019; 1953():151-162. PubMed ID: 30912021
[TBL] [Abstract][Full Text] [Related]
18. Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.
Carvalho MR; Lima D; Reis RL; Oliveira JM; Correlo VM
Stem Cell Rev Rep; 2017 Jun; 13(3):347-363. PubMed ID: 28233276
[TBL] [Abstract][Full Text] [Related]
19. Beyond 3D culture models of cancer.
Tanner K; Gottesman MM
Sci Transl Med; 2015 Apr; 7(283):283ps9. PubMed ID: 25877888
[TBL] [Abstract][Full Text] [Related]
20. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs.
Santo VE; Rebelo SP; Estrada MF; Alves PM; Boghaert E; Brito C
Biotechnol J; 2017 Jan; 12(1):. PubMed ID: 27966285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
